• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

帕博利珠单抗治疗浸润性膀胱尿路上皮癌患者后出现未分化尿路上皮癌：一例报告

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report.

作者信息

Hasegawa Moto, Hasegawa Go, Ikeda Yohei, Hara Noboru, Nishiyama Tsutomu

机构信息

Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.

Department of Pathology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan.

出版信息

SAGE Open Med Case Rep. 2020 Jun 13;8:2050313X20932694. doi: 10.1177/2050313X20932694. eCollection 2020.

DOI:10.1177/2050313X20932694
PMID:32587697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7294485/
Abstract

An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, the tumor disappeared. After 15 courses of the treatment, the tumor regrew. Pathological findings revealed invasive undifferentiated urothelial carcinoma consisting of relatively small tumor cells of the same size as lymphocytes, negative for neuroendocrine markers. Programmed death-ligand 1 expressions in tumor tissue changed from positive before treatment to negative after pembrolizumab treatment.

摘要

一名83岁男性在接受吉西他滨和顺铂的抗癌化疗后，因晚期膀胱癌接受了帕博利珠单抗治疗。病理检查结果显示，治疗前为伴有鳞状分化的浸润性尿路上皮癌。经过七个疗程的帕博利珠单抗治疗后，肿瘤消失。在接受15个疗程的治疗后，肿瘤复发。病理检查结果显示为浸润性未分化尿路上皮癌，由与淋巴细胞大小相同的相对较小的肿瘤细胞组成，神经内分泌标志物呈阴性。肿瘤组织中程序性死亡配体1的表达从治疗前的阳性变为帕博利珠单抗治疗后的阴性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/5967a03bdbb2/10.1177_2050313X20932694-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/833c3b518e15/10.1177_2050313X20932694-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/c606d7765d3b/10.1177_2050313X20932694-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/3ba55efb6a62/10.1177_2050313X20932694-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/5967a03bdbb2/10.1177_2050313X20932694-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/833c3b518e15/10.1177_2050313X20932694-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/c606d7765d3b/10.1177_2050313X20932694-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/3ba55efb6a62/10.1177_2050313X20932694-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a14/7294485/5967a03bdbb2/10.1177_2050313X20932694-fig4.jpg

相似文献

1
Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report.帕博利珠单抗治疗浸润性膀胱尿路上皮癌患者后出现未分化尿路上皮癌：一例报告
SAGE Open Med Case Rep. 2020 Jun 13;8:2050313X20932694. doi: 10.1177/2050313X20932694. eCollection 2020.
2
Metastatic Urothelial Carcinoma With Sarcomatoid Subtype After Robot-Assisted Radical Cystectomy Successfully Treated With Pembrolizumab.机器人辅助根治性膀胱切除术后出现肉瘤样亚型的转移性尿路上皮癌经派姆单抗成功治疗
Cureus. 2024 Jun 7;16(6):e61871. doi: 10.7759/cureus.61871. eCollection 2024 Jun.
3
Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report.一名化疗耐药的上尿路尿路上皮癌患者对新辅助派姆单抗的完全病理反应：病例报告
Front Oncol. 2020 Sep 24;10:564714. doi: 10.3389/fonc.2020.564714. eCollection 2020.
4
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.FDA 批准概要：阿替利珠单抗或帕博利珠单抗用于治疗不符合顺铂化疗条件的晚期尿路上皮癌患者。
Oncologist. 2019 Apr;24(4):563-569. doi: 10.1634/theoncologist.2018-0084. Epub 2018 Dec 12.
5
Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report.顺铂/吉西他滨联合替雷利珠单抗治疗后复杂浸润性尿路上皮癌的膀胱保留：一例报告
World J Clin Cases. 2023 Feb 16;11(5):1165-1174. doi: 10.12998/wjcc.v11.i5.1165.
6
Successful treatment of metastatic bladder cancer by gemcitabine-cisplatin re-challenge after pembrolizumab.帕博利珠单抗治疗后吉西他滨-顺铂再次挑战成功治疗转移性膀胱癌。
IJU Case Rep. 2021 Jul 20;4(6):360-362. doi: 10.1002/iju5.12348. eCollection 2021 Nov.
7
Progressive plasmacytoid variant bladder cancer with retroperitoneal dissemination: An autopsy case report.伴腹膜后播散的进行性浆细胞样变异型膀胱癌：一例尸检病例报告
IJU Case Rep. 2020 May 28;3(5):166-169. doi: 10.1002/iju5.12167. eCollection 2020 Sep.
8
Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report.帕博利珠单抗治疗一名复发性和转移性尿路上皮膀胱癌患者取得完全缓解，该患者同时存在肉瘤样亚型和腺性分化：一例病例报告
Int Cancer Conf J. 2022 Aug 6;12(1):24-30. doi: 10.1007/s13691-022-00568-5. eCollection 2023 Jan.
9
Successful Resection of Cisplatin-Resistant Renal Pelvic Cancer after the Administration of Pembrolizumab as Second-Line Therapy.帕博利珠单抗二线治疗后成功切除顺铂耐药肾盂癌
Case Rep Oncol. 2019 Jul 16;12(2):548-553. doi: 10.1159/000501715. eCollection 2019 May-Aug.
10
First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.一线帕博利珠单抗治疗铂类不适用的浆细胞样尿路上皮癌患者：一例报告
J Oncol Pharm Pract. 2020 Jan;26(1):216-219. doi: 10.1177/1078155219835006. Epub 2019 Mar 4.

引用本文的文献

1
The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.免疫检查点抑制剂治疗与化疗治疗晚期和转移性尿路上皮癌的疗效比较：一项荟萃分析。
J Cancer Res Clin Oncol. 2024 Jan 3;150(1):5. doi: 10.1007/s00432-023-05584-3.
2
Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review.单独使用PD-1抑制剂有效治疗孤立性肾盏尿路上皮癌：一例报告及文献综述
Front Oncol. 2022 May 10;12:866013. doi: 10.3389/fonc.2022.866013. eCollection 2022.

本文引用的文献

1
Mechanisms Controlling PD-L1 Expression in Cancer.肿瘤中 PD-L1 表达的调控机制。
Mol Cell. 2019 Nov 7;76(3):359-370. doi: 10.1016/j.molcel.2019.09.030. Epub 2019 Oct 24.
2
The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.PD-L1 在尿路上皮癌中的临床病理和预后价值：一项荟萃分析。
Clin Exp Med. 2019 Nov;19(4):407-416. doi: 10.1007/s10238-019-00572-9. Epub 2019 Aug 12.
3
Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
肌层浸润性膀胱癌和上尿路尿路上皮癌患者化疗与手术的最佳时机
Urol Clin North Am. 2018 May;45(2):155-167. doi: 10.1016/j.ucl.2017.12.002. Epub 2018 Feb 21.
4
Histologic Transformation in NSCLC with PD-1 therapy.非小细胞肺癌中PD-1治疗后的组织学转化
J Thorac Oncol. 2017 Sep;12(9):e133-e134. doi: 10.1016/j.jtho.2017.04.026. Epub 2017 May 10.
5
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.帕博利珠单抗作为晚期尿路上皮癌的二线治疗药物。
N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.
6
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.非小细胞肺癌向小细胞肺癌的转变：分子驱动因素及起源细胞
Lancet Oncol. 2015 Apr;16(4):e165-72. doi: 10.1016/S1470-2045(14)71180-5.
7
Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?膀胱癌患者中可疑的尿液细胞学检查结果（III级）：应将其视为阴性还是阳性？
Scand J Urol Nephrol. 2002;36(3):213-7. doi: 10.1080/003655902320131901.